A study published in npj Biofilms and Microbiomes explores the increasingly researched concept of how the gut microbiota influences the development of obesity and type 2 diabetes through the so-called gut-brain axis.
The review highlights that the gut microbiota is far more than a passive ecosystem. Instead, it acts as an active regulator of metabolism and inflammation. Gut microbes produce and modify a wide range of biologically active compounds, including short-chain fatty acids, bile acids, neuroactive molecules, and extracellular vesicles. These signaling molecules can affect the brain, immune system, and metabolic processes throughout the body.
A central player in this regulatory network is the hypothalamus, the region of the brain responsible for maintaining energy balance by coordinating food intake and energy expenditure. Under normal conditions, microbial metabolites—particularly short-chain fatty acids—promote feelings of satiety and increase energy consumption. However, when the gut microbiota becomes imbalanced, a condition known as dysbiosis, these beneficial effects are diminished.
According to the authors, diets high in fat combined with microbial imbalance can increase the leakage of bacterial components such as lipopolysaccharides into the bloodstream. This process triggers inflammatory responses and reduces the hypothalamus's sensitivity to insulin, a mechanism considered to be one of the early drivers of obesity.
At the same time, adipose tissue ceases to function merely as an energy storage site and becomes an active source of inflammatory signals. It releases cytokines and free fatty acids that amplify systemic inflammation and may disrupt the blood-brain barrier, further affecting appetite regulation and metabolic control.
The review also examines the role of gut-derived hormones, including glucagon-like peptide-1 (GLP-1) and peptide YY (PYY), which help regulate satiety and insulin function. Dysbiosis has been associated with reduced production of these hormones, weakening signals of fullness and potentially promoting overeating.
The authors further explore the relationship between the gut microbiota and type 2 diabetes. When the intestinal barrier becomes compromised, bacterial products can reach the liver, activate immune cells, and trigger inflammation that interferes with normal insulin signaling. Similar inflammatory processes can impair insulin sensitivity in muscles and other tissues throughout the body.
The study also describes a self-perpetuating cycle in which inflammation worsens metabolic dysfunction, while metabolic disturbances further fuel inflammation. Over time, this cycle may contribute to the progression of both obesity and type 2 diabetes.
The researchers suggest that future therapeutic strategies could focus on restoring microbial balance through approaches such as prebiotics, probiotics, and metabolic modulation of key signaling pathways. However, they emphasize that the effectiveness of these interventions is likely to depend on individual factors, including genetics, diet, baseline microbiota composition, and the stage of disease.
Follow NEWS.am Medicine on Facebook and Twitter